Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-20 11:38 CEST (UTC+2h)
Ramesh Ramalingam
Junior

India,
2017-09-05 07:35

Posting: # 17776
Views: 2,523
 

 subject inclusion criteria in PK and stat and BE conclusion [Regulatives / Guidelines]

Dear All,

I have more doubt on subject inclusion criteria for pharmacokinetic and statistical analysis in fully replicate (Including NTI drugs) and partial replicate design BE studies. could you please suggest the subject inclusion criteria for PK and stat analysis (including who's data can be considered for BE)? Also, How many treatment periods subject should be completed in the study?



Regards,
Ramesh Ramalingam
ElMaestro
Hero

Denmark,
2017-09-05 08:26

@ Ramesh Ramalingam
Posting: # 17777
Views: 2,295
 

 subject inclusion criteria in PK and stat and BE conclusion

Hi Ramesh,

Statistics:
EU: Include those who provide both a Test and Reference period.
US: Include those who provide data.

Descriptive PK: Done on all data as much as possible.

I have a feeling you may have asked about something else, though?

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
Ramesh Ramalingam
Junior

India,
2017-09-05 09:17
(edited by Ohlbe on 2017-09-05 09:59)

@ ElMaestro
Posting: # 17778
Views: 2,306
 

 subject inclusion criteria in PK and stat and BE conclusion

Dear ElMaestro,

Thank you very much for your response.

Based on your response i understand that the subject inclusion criteria for pharmacokinetic and statistical analysis as follows for NTI drugs:

SWR calculations & SWT calculations & Average BE: subject should completed all the study periods
SWR calculations & Average BE:subject who completed with Reference twice and Test once
SWT calculations & Average BE:subject who completed with Reference once and Test twice
SWR calculations:subject who completed with Reference twice
SWT calculations:subject who completed with Test twice

Based on this subject should complete at least two treatment periods of the study wright?

for HVDs(fully replicate design):

SWR calculations & Average BE: subject who completed all the study periods
SWR calculations:subject who completed with Reference twice
Average BE:Subject who complete at least one test and one reference treatment

Hence, Subject should complete at least one test and one reference treatment period or both reference treatment periods of the study, wright?

Kindly advice if anything wrong.

Regards,
Ramesh Ramalingam


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]
ElMaestro
Hero

Denmark,
2017-09-05 09:20

@ Ramesh Ramalingam
Posting: # 17779
Views: 2,245
 

 subject inclusion criteria in PK and stat and BE conclusion

Hi Ramesh,

please be specific: are you targeting US or EU or some other territory?

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
Ramesh Ramalingam
Junior

India,
2017-09-05 09:22

@ ElMaestro
Posting: # 17780
Views: 2,270
 

 subject inclusion criteria in PK and stat and BE conclusion

» please be specific: are you targeting US or EU or some other territory?

US
ElMaestro
Hero

Denmark,
2017-09-05 10:16

@ Ramesh Ramalingam
Posting: # 17781
Views: 2,288
 

 subject inclusion criteria in PK and stat and BE conclusion

Hi Ramesh,

» US

Then all variance components come from a mixed model that has been fit using REML. Any subject who has an R or T value or any quantity of both contributes (let's leave 'outliers' and aberrant values out for the purpose of this discussion).

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
yicaoting
Regular

NanKing, China,
2017-09-05 15:23

@ Ramesh Ramalingam
Posting: # 17782
Views: 2,232
 

 At least twice R or twice T for sWR and sWT

» SWR calculations:subject who completed with Reference twice
» SWT calculations:subject who completed with Test twice

For NTID, if you apply the formula to calc sWR or sWT, you MUST have at least twice R or twice T.
Those subjects with only one R, will have no contribution in calculating sWR. Similar to that of sWT.
This is just for sWR and sWT, and sWR/sWT and it's %CI.
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,192 registered users;
online 17 (1 registered, 16 guests [including 11 identified bots]).

If there is an exception to any rule,
and if it can be proved by observation,
that rule is wrong.    Richard Feynman

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed